Navigation Links
Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
Date:10/8/2009

QUEBEC CITY, Oct. 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center ("ECBC") Research & Technology Directorate. Medicago will work with ECBC to investigate the affordable production of industrial enzymes in the field of biofuels. This new project builds on Medicago's proprietary plant-based manufacturing platform and its potential for applications beyond the biological drug market.

"While we remain focused on advancing our core influenza programs, biotechnology markets are quickly evolving and offer new opportunities to increase shareholder value," said Louis P. Vezina, Chief Scientific Officer of Medicago. "The world enzyme market is currently estimated to be worth US$4 billion and is projected to increase 5.7% per year. Moreover, the high cost of enzymes is a major hurdle in the production of biofuels using biomass. We believe our manufacturing platform could be suitable for the production of affordable enzymes as plants are uniquely capable of efficient protein expression at high yields and low costs. We look forward to playing a role in the U.S. Army's efforts to accelerate the economical production of biofuels."

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technolog
'/>"/>

SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medicago begins human clinical testing with its avian flu pandemic vaccine
2. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago succesfully expresses VLP antigen for A H1N1 strain
5. Medicago initiates work on Swine Flu strain
6. NeoStem, Inc. Awarded NIH Research and Research Infrastructure Grand Opportunities Grant
7. Morphotek(R), Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins
8. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
9. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
10. Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness
11. Hanson Technologies, Inc. Awarded Patent for its Advanced Food Pathogen Detection System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
(Date:10/19/2014)... Latin American hardware encryption display market report defines and ... forecast of revenue. This market was valued at $165.0 ... million by 2018, at a CAGR of 70.3% from ... the Latin American hardware encryption market report to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/19/2014)... 19, 2014 The Asian Automatic patient ... with analysis and forecast of revenue. The Automatic patient ... around $463.9 million by 2018, at a developing CAGR ... the TOC of the Asian Automatic patient billing market, ... This also provides a glimpse of the segmentation of ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... Program Combines Histology, Biomarkers and Non-Invasive Imaging to Demonstrate ... FRANCISCO, May 14 VIA Pharmaceuticals, Inc. ... on the development of compounds for the treatment of ... completed enrollment in a Phase 2 clinical trial of ...
... manufacturing facility opens with substantially increased capacity, ... Biosystems Inc. (TSX:MBX) announced today robust double digit growth ... for the second quarter ended March 31, 2009. , ... of Microbix said "Our 43% growth in the first ...
... The Netherlands, May 14 Nucletron, a,knowledge-based ... new release,of Oncentra(R) Brachy, a comprehensive film- ... treatment planning for brachytherapy.,Oncentra Brachy, the world,s ... user-friendly Windows-based planning system that features,state-of-the-art optimization ...
Cached Biology Technology:VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions 2
(Date:10/14/2014)... new study published in Cancer Research shows ... and colon cancers—can promote the development of skin cancers ... and survival of sun-damaged skin cells. , Previously considered ... proteins called sirtuins that help regulate genomic stability and ... SIRT6 helps repair DNA damage, which can lead to ...
(Date:10/14/2014)... a new kind of stem cell that can become either ... vessels, according to a study published today in the journal ... cell type contradicts current theory on how organs arise from ... origins of, and future treatment for, liver cancer., Thanks to ... complex being made up of more than 200 cell types. ...
(Date:10/14/2014)... by the Chinese Academy of Agricultural Sciences in Beijing, ... brief genomic history of tomato breeding, based on sequencing ... C.M. Rick Tomato Genetics Resource Center at UC Davis ... seed of both cultivated tomato varieties and related wild ... tomato genome sequence completed just two years ago, shows ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... Strasbourg 18/04/12 - Technology has transformed the way humans interact ... big ideas that will drive growth in marine and maritime ... and policy will gather at the 3rd Marine Board Forum ... Marine Board has convened this flagship event on the understanding ...
... ecologist and entomologist at the University of Guam has just ... weed Mikania micrantha . The mile-a-minute vine is ... Pacific. Mikania,s native range is the tropical and subtropical areas ... on the top ten list of important weeds of Pacific ...
... results presented at 3rd European Lung Cancer Conference in ... the diagnosis and treatment of malignant pleural mesothelioma, an ... caused by asbestos exposure. Micro RNAs speed ... molecule that is more abundant in the blood of ...
Cached Biology News:New technologies for a blue future 2Weeding out invasive species with classical biological control 2Promising developments in early diagnosis and treatment of mesothelioma 2Promising developments in early diagnosis and treatment of mesothelioma 3Promising developments in early diagnosis and treatment of mesothelioma 4
...
BD IMagnet 1 each...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Biology Products: